Peek Health Health Care为生物相似的Stelara推出直接定价,以降低病人和雇主的成本。 Peek Healthcare launches direct pricing for biosimilar Stelara to cut costs for patients and employers.

Peek保健技术公司为IMULDOSA启动了PeekDirectTM定价,这是与Stelaraí相似的生物,提供直接到雇主和直接到病人的定价,以降低特殊药品的成本。 Peek Healthcare Technologies has launched PeekDirect™ pricing for IMULDOSA®, a biosimilar to Stelara®, offering direct-to-employer and direct-to-patient pricing to lower costs for specialty medications. 该药物可治疗克罗恩病、溃疡性结肠炎、牛皮癣和银屑病关节炎等自身免疫性疾病。 The drug treats autoimmune conditions like Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. 该方案通过Peek Meds市场提供,绕过传统的以回扣为基础的定价,消除隐藏的印记,并在处方时提供透明、较低的费用。 Available through the Peek Meds Marketplace, the program bypasses traditional rebate-based pricing, eliminating hidden markups and providing transparent, lower costs at prescription. 该倡议旨在改善患者和雇主获得服务的机会,并减少财政障碍。 The initiative aims to improve access and reduce financial barriers for patients and employers.